Gain Therapeutics, Inc. (GANX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company tackles some of the most challenging neurodegenerative diseases? Gain Therapeutics Inc. (GANX), with a market capitalization of $45.85 million as of April 2025, is pioneering novel small molecule therapeutics, but what exactly does that mean for the future of treating conditions like Parkinson's and Alzheimer's? Keep reading to discover how Gain's innovative Magellan platform and lead drug candidate, GT-02287, are making waves in the biotechnology world, potentially reaching peak revenues of $800 million by 2040.

Gain Therapeutics, Inc. (GANX) History

Gain Therapeutics Founding Timeline

Year established

Gain Therapeutics, Inc. was founded in 2017.

Original location

The company was originally located in Lugano, Switzerland.

Founding team members

The founding team included:

• Khalil Essani, Ph.D.
• Rosario Giovanni Stratico, M.D.

Initial capital/funding

In 2017, Gain Therapeutics launched with a $12 million Series A financing round led by Vita Ventures and co-led by TiVenture.

Gain Therapeutics Evolution Milestones

Gain Therapeutics Transformative Moments

• Initial Public Offering (IPO): Going public in 2020 provided Gain Therapeutics with significant capital to advance its research and development programs. The $46 million raised allowed for expanded clinical trials and pipeline development.
• IND Submission for GT-02287: The submission of the IND application for GT-02287 in 2022 marked a critical step in the company's clinical development pathway. This milestone paved the way for human trials and potential treatments for severe neurodegenerative diseases.
• Strategic Partnerships: Forming collaborations with other companies and research institutions has broadened Gain Therapeutics' capabilities and resources, accelerating the discovery and development of novel therapeutics.

For more information, explore: Mission Statement, Vision, & Core Values of Gain Therapeutics, Inc. (GANX).

Gain Therapeutics, Inc. (GANX) Ownership Structure

Understanding the ownership structure of Gain Therapeutics, Inc. provides valuable insights into the company’s control and governance. The details of ownership help stakeholders understand who has influence over company decisions.

Gain Therapeutics, Inc. Current Status

Gain Therapeutics, Inc. is a publicly traded company, which means its shares are available for purchase by the general public on a stock exchange.

Gain Therapeutics, Inc. Ownership Breakdown

The ownership of Gain Therapeutics, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. Here is a breakdown:

Gain Therapeutics, Inc. Leadership

The leadership team at Gain Therapeutics, Inc. is responsible for the strategic direction and operational management of the company. Key members include:

• Eric Richman: Chief Executive Officer
• Khaled Djerassi: Chief Medical Officer
• Matthias Alder: Chief Financial Officer

To gain more insight into the company's goals, see Mission Statement, Vision, & Core Values of Gain Therapeutics, Inc. (GANX).

Gain Therapeutics, Inc. (GANX) Mission and Values

Gain Therapeutics is dedicated to developing novel therapies for severe diseases characterized by protein misfolding. The company's core values center around innovation, patient focus, and scientific excellence, driving their efforts to address unmet medical needs.

Gain Therapeutics' Core Purpose

Official mission statement

Gain Therapeutics' mission is to discover and develop transformative therapies for patients suffering from genetically defined diseases characterized by protein misfolding. This involves:

• Developing novel and proprietary structurally targeted allosteric regulators (STARs).
• Focusing on restoring or stabilizing the native 3D structure of misfolded proteins.
• Targeting the root cause of disease to provide meaningful clinical benefits.

Vision statement

While a specific vision statement is not explicitly available in the provided context, Gain Therapeutics' actions and goals suggest a vision focused on:

• Becoming a leader in developing treatments for diseases caused by protein misfolding.
• Expanding the application of their STARs platform to address a wide range of genetic diseases.
• Improving the lives of patients with limited or no treatment options.

Company slogan/tagline

Based on available information, Gain Therapeutics does not have a widely publicized official slogan or tagline. However, considering their focus, a potential implied tagline could be:

• Restoring Structure, Restoring Health.
• Targeting the Root Cause for a Healthier Future.

For more in-depth information, visit: Mission Statement, Vision, & Core Values of Gain Therapeutics, Inc. (GANX).

Gain Therapeutics, Inc. (GANX) How It Works

Gain Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for genetically defined neurological diseases, utilizing its proprietary platform, SEE-Tx™, to identify and develop structurally targeted allosteric regulators (STARs). These STARs are designed to restore or improve the activity of key proteins involved in disease progression.

Gain Therapeutics, Inc.'s Product/Service Portfolio

Gain Therapeutics, Inc.'s Operational Framework

Gain Therapeutics operates through a focused drug development process centered on its SEE-Tx™ platform. The operational framework includes:

• Target Identification: Identifying key proteins that are misfolded or dysfunctional in genetically defined diseases.
• STARs Development: Designing and synthesizing STARs that can bind to these proteins and restore their proper function.
• Preclinical Testing: Conducting in vitro and in vivo studies to evaluate the efficacy, safety, and pharmacokinetic properties of STARs.
• Clinical Trials: Progressing promising STAR candidates into Phase 1, Phase 2, and Phase 3 clinical trials to assess their safety and efficacy in human patients.
• Partnerships: Collaborating with research institutions and pharmaceutical companies to expand its pipeline and accelerate drug development.

For more insights into the financial aspects, consider reading: Breaking Down Gain Therapeutics, Inc. (GANX) Financial Health: Key Insights for Investors

Gain Therapeutics, Inc.'s Strategic Advantages

Gain Therapeutics' strategic advantages stem from its innovative technology and focused approach:

• SEE-Tx™ Platform: A proprietary platform that enables the rational design of STARs, offering a competitive edge in developing novel therapies for complex diseases.
• Targeted Approach: Focus on genetically defined diseases allows for a more precise and potentially more effective therapeutic intervention.
• Orally Available Drugs: Developing orally administered drugs provides convenience and improves patient compliance.
• Blood-Brain Barrier Penetration: Designing drugs that can cross the blood-brain barrier is crucial for treating neurological diseases, a capability built into their drug development strategy.
• Experienced Team: A management team with a strong background in drug discovery and development.

Gain Therapeutics, Inc. (GANX) How It Makes Money

Gain Therapeutics, Inc. focuses on discovering and developing new treatments for severe diseases characterized by protein misfolding, leveraging its proprietary platform called SEE-Tx™ to identify novel allosteric binding sites and design molecules that restore protein folding and function.

Gain Therapeutics, Inc. Revenue Breakdown

As a clinical-stage biotechnology company, Gain Therapeutics currently does not generate revenue from product sales. Its primary source of funding comes from strategic partnerships, research grants, and investments. Given its stage, revenue streams are not yet diversified.

Gain Therapeutics, Inc. Business Economics

Gain Therapeutics operates under a business model common to biotechnology companies focused on drug discovery and development. Key aspects of its business economics include:

• Drug Development Costs: Significant investment in research and development, preclinical studies, and clinical trials.
• Intellectual Property: Patents and proprietary technology (SEE-Tx™ platform) are crucial assets that can be licensed or partnered.
• Partnerships: Collaborations with larger pharmaceutical companies can provide substantial upfront payments, milestone payments, and royalties on future sales.
• Funding: Relies on venture capital, public offerings, and grants to fund operations until a product reaches the market.
• Pricing Strategy: If a drug is approved, pricing will likely be based on the value it provides to patients and healthcare systems, considering factors like efficacy, safety, and competitive landscape.

Gain Therapeutics, Inc. Financial Performance

As of the fiscal year 2024, Gain Therapeutics' financial performance reflects its status as a research and development company. Key points include:

• R&D Expenses: A significant portion of operating expenses is dedicated to research and development.
• Cash Runway: Monitoring cash reserves is vital to ensure the company can fund its operations through critical milestones.
• Net Loss: As is typical for biotech companies in the development phase, Gain Therapeutics is likely to report a net loss.
• Strategic Investments: Investment in its SEE-Tx™ platform and pipeline programs aimed at long-term growth.

To gain more insights into Gain Therapeutics, Inc., consider reading: Exploring Gain Therapeutics, Inc. (GANX) Investor Profile: Who’s Buying and Why?

Gain Therapeutics, Inc. (GANX) Market Position & Future Outlook

Gain Therapeutics is strategically positioned to address significant unmet needs in neurodegenerative diseases and cancer by leveraging its proprietary platform, SEE-Tx. Their future outlook hinges on the successful development and clinical validation of their lead programs targeting genetically defined diseases.

Competitive Landscape

Opportunities & Challenges

Industry Position

Gain Therapeutics is an emerging player in the biotechnology sector, focusing on innovative approaches to treat diseases caused by protein misfolding. Its position can be further described by:

• Novel Approach: The company's SEE-Tx platform offers a unique approach to drug discovery by identifying allosteric binding sites on misfolded proteins.
• Targeted Therapies: Gain is concentrating on genetically defined diseases, allowing for a more precise and potentially effective therapeutic strategy.
• Early Stage: As a company with products in early clinical development, it has substantial growth potential but also faces significant risks.

To gain a deeper understanding of the company's core values and strategic vision, explore: Mission Statement, Vision, & Core Values of Gain Therapeutics, Inc. (GANX).